drugset
drugset / Trial / NCT03839446

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

NCT03839446 ↗

Phase 2 Completed 16 enrolled Robert Redner, MD Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, single arm phase II study which will examine the efficacy and toxicity of the combination therapy of GO, mitoxantrone and etoposide in patients who did not respond to first line induction therapy.

Timeline

Start
2019-02-28
Primary completion
2023-02-02
Completion
2024-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Gemtuzumab Ozogamicin Monoclonal antibody 3 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 10 mg/m2 Intravenous

Indications

acute myeloid leukemia